Cargando…

Response to roxadustat in a patient undergoing long-term dialysis and allergic to erythropoiesis-stimulating agents: A case report

BACKGROUND: Hypoxia-inducible factor prolyl hydroxylase inhibitor is a new class of drugs for treating renal anemia. It is a second-generation hypoxia-inducible factor prolyl hydroxylase-2 (PHD2) inhibitor. Roxadustat can effectively increase hemoglobin in patients with dialysis-dependent chronic ki...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Cai, Luo, Deng-Gui, Liu, Zhe-Yan, Yang, Dong, Wang, Dan-Dan, Xu, Yuan-Zhao, Yang, Jun, Fu, Bo, Qi, Ai-Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782933/
https://www.ncbi.nlm.nih.gov/pubmed/36568993
http://dx.doi.org/10.12998/wjcc.v10.i35.13122
_version_ 1784857457200201728
author Xu, Cai
Luo, Deng-Gui
Liu, Zhe-Yan
Yang, Dong
Wang, Dan-Dan
Xu, Yuan-Zhao
Yang, Jun
Fu, Bo
Qi, Ai-Rong
author_facet Xu, Cai
Luo, Deng-Gui
Liu, Zhe-Yan
Yang, Dong
Wang, Dan-Dan
Xu, Yuan-Zhao
Yang, Jun
Fu, Bo
Qi, Ai-Rong
author_sort Xu, Cai
collection PubMed
description BACKGROUND: Hypoxia-inducible factor prolyl hydroxylase inhibitor is a new class of drugs for treating renal anemia. It is a second-generation hypoxia-inducible factor prolyl hydroxylase-2 (PHD2) inhibitor. Roxadustat can effectively increase hemoglobin in patients with dialysis-dependent chronic kidney disease, with an adverse events profile comparable to that of epoetin alfa. We administered roxadustat to a maintenance hemodialysis patient who was allergic to erythropoiesis-stimulating agents (ESAs) and depended on blood transfusion for five years. After applying Roxadustat, the patient’s anemia improved significantly. CASE SUMMARY: A 77-year-old Chinese man had type 2 diabetes for 16 years, underwent maintenance hemodialysis for five years, and had fatigue for five years. Laboratory tests showed severe anemia (hemoglobin concentration of 42 g/L). The patient was administered a subcutaneous injection of ESAs before dialysis. He suffered an allergic shock immediately and fainted. His blood pressure dropped to undetectable levels. He was not administered ESAs henceforth. The patient was prescribed iron supplements and received blood transfusions occasionally for five years. His hemoglobin concentration ranged from 42-68 g/L. After taking six weeks of oral roxadustat three times weekly (100 mg TIW), the patient’s hemoglobin concentration increased significantly, and his symptoms decreased. We adjusted the doses of roxadustat, and the hemoglobin concentration was maintained between 97 and 126 g/L. CONCLUSION: Oral roxadustat is effective in treating anemia in maintenance hemodialysis patients who cannot be administered ESAs.
format Online
Article
Text
id pubmed-9782933
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-97829332022-12-24 Response to roxadustat in a patient undergoing long-term dialysis and allergic to erythropoiesis-stimulating agents: A case report Xu, Cai Luo, Deng-Gui Liu, Zhe-Yan Yang, Dong Wang, Dan-Dan Xu, Yuan-Zhao Yang, Jun Fu, Bo Qi, Ai-Rong World J Clin Cases Case Report BACKGROUND: Hypoxia-inducible factor prolyl hydroxylase inhibitor is a new class of drugs for treating renal anemia. It is a second-generation hypoxia-inducible factor prolyl hydroxylase-2 (PHD2) inhibitor. Roxadustat can effectively increase hemoglobin in patients with dialysis-dependent chronic kidney disease, with an adverse events profile comparable to that of epoetin alfa. We administered roxadustat to a maintenance hemodialysis patient who was allergic to erythropoiesis-stimulating agents (ESAs) and depended on blood transfusion for five years. After applying Roxadustat, the patient’s anemia improved significantly. CASE SUMMARY: A 77-year-old Chinese man had type 2 diabetes for 16 years, underwent maintenance hemodialysis for five years, and had fatigue for five years. Laboratory tests showed severe anemia (hemoglobin concentration of 42 g/L). The patient was administered a subcutaneous injection of ESAs before dialysis. He suffered an allergic shock immediately and fainted. His blood pressure dropped to undetectable levels. He was not administered ESAs henceforth. The patient was prescribed iron supplements and received blood transfusions occasionally for five years. His hemoglobin concentration ranged from 42-68 g/L. After taking six weeks of oral roxadustat three times weekly (100 mg TIW), the patient’s hemoglobin concentration increased significantly, and his symptoms decreased. We adjusted the doses of roxadustat, and the hemoglobin concentration was maintained between 97 and 126 g/L. CONCLUSION: Oral roxadustat is effective in treating anemia in maintenance hemodialysis patients who cannot be administered ESAs. Baishideng Publishing Group Inc 2022-12-16 2022-12-16 /pmc/articles/PMC9782933/ /pubmed/36568993 http://dx.doi.org/10.12998/wjcc.v10.i35.13122 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Case Report
Xu, Cai
Luo, Deng-Gui
Liu, Zhe-Yan
Yang, Dong
Wang, Dan-Dan
Xu, Yuan-Zhao
Yang, Jun
Fu, Bo
Qi, Ai-Rong
Response to roxadustat in a patient undergoing long-term dialysis and allergic to erythropoiesis-stimulating agents: A case report
title Response to roxadustat in a patient undergoing long-term dialysis and allergic to erythropoiesis-stimulating agents: A case report
title_full Response to roxadustat in a patient undergoing long-term dialysis and allergic to erythropoiesis-stimulating agents: A case report
title_fullStr Response to roxadustat in a patient undergoing long-term dialysis and allergic to erythropoiesis-stimulating agents: A case report
title_full_unstemmed Response to roxadustat in a patient undergoing long-term dialysis and allergic to erythropoiesis-stimulating agents: A case report
title_short Response to roxadustat in a patient undergoing long-term dialysis and allergic to erythropoiesis-stimulating agents: A case report
title_sort response to roxadustat in a patient undergoing long-term dialysis and allergic to erythropoiesis-stimulating agents: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782933/
https://www.ncbi.nlm.nih.gov/pubmed/36568993
http://dx.doi.org/10.12998/wjcc.v10.i35.13122
work_keys_str_mv AT xucai responsetoroxadustatinapatientundergoinglongtermdialysisandallergictoerythropoiesisstimulatingagentsacasereport
AT luodenggui responsetoroxadustatinapatientundergoinglongtermdialysisandallergictoerythropoiesisstimulatingagentsacasereport
AT liuzheyan responsetoroxadustatinapatientundergoinglongtermdialysisandallergictoerythropoiesisstimulatingagentsacasereport
AT yangdong responsetoroxadustatinapatientundergoinglongtermdialysisandallergictoerythropoiesisstimulatingagentsacasereport
AT wangdandan responsetoroxadustatinapatientundergoinglongtermdialysisandallergictoerythropoiesisstimulatingagentsacasereport
AT xuyuanzhao responsetoroxadustatinapatientundergoinglongtermdialysisandallergictoerythropoiesisstimulatingagentsacasereport
AT yangjun responsetoroxadustatinapatientundergoinglongtermdialysisandallergictoerythropoiesisstimulatingagentsacasereport
AT fubo responsetoroxadustatinapatientundergoinglongtermdialysisandallergictoerythropoiesisstimulatingagentsacasereport
AT qiairong responsetoroxadustatinapatientundergoinglongtermdialysisandallergictoerythropoiesisstimulatingagentsacasereport